These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15675606)

  • 1. Adenine nucleotides and dinucleotides as new substances for the treatment of ocular hypertension and glaucoma.
    Pintor J
    Curr Opin Investig Drugs; 2005 Jan; 6(1):76-80. PubMed ID: 15675606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypotensive effect of UDP on intraocular pressure in rabbits.
    Markovskaya A; Crooke A; Guzmán-Aranguez AI; Peral A; Ziganshin AU; Pintor J
    Eur J Pharmacol; 2008 Jan; 579(1-3):93-7. PubMed ID: 18031728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dinucleoside polyphosphates on trabecular meshwork cells and aqueous humor outflow facility.
    Soto D; Pintor J; Peral A; Gual A; Gasull X
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1042-51. PubMed ID: 15947035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Steroid induced ocular hypertension and glaucoma].
    Călugăru D; Călugăru M
    Oftalmologia; 2009; 53(3):15-33. PubMed ID: 19899544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The logic behind target intraocular pressure.
    Coleman AL; Caprioli J
    Am J Ophthalmol; 2009 Mar; 147(3):379-80. PubMed ID: 19217951
    [No Abstract]   [Full Text] [Related]  

  • 7. New treatments for ocular hypertension.
    Mediero A; Alarma-Estrany P; Pintor J
    Auton Neurosci; 2009 May; 147(1-2):14-9. PubMed ID: 19176290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenine nucleotide effect on intraocular pressure: Involvement of the parasympathetic nervous system.
    Peral A; Gallar J; Pintor J
    Exp Eye Res; 2009 Jun; 89(1):63-70. PubMed ID: 19250934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
    Harrison BA; Whitlock NA; Voronkov MV; Almstead ZY; Gu KJ; Mabon R; Gardyan M; Hamman BD; Allen J; Gopinathan S; McKnight B; Crist M; Zhang Y; Liu Y; Courtney LF; Key B; Zhou J; Patel N; Yates PW; Liu Q; Wilson AG; Kimball SD; Crosson CE; Rice DS; Rawlins DB
    J Med Chem; 2009 Nov; 52(21):6515-8. PubMed ID: 19831390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
    Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
    Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nucleotides as a new alternative for the treatment of ocular hypertension].
    Pintor J
    Arch Soc Esp Oftalmol; 2003 Jun; 78(6):295-6. PubMed ID: 12838460
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aqueous humor flow measured by fluorophotometry. A comparative study of the effect of various beta-blocker eyedrops in patients with ocular hypertension].
    Coulangeon LM; Sole M; Menerath JM; Sole P
    Ophtalmologie; 1990; 4(2):156-61. PubMed ID: 2235007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dinucleoside polyphosphates in the eye: from physiology to therapeutics.
    Guzmán-Aranguez A; Crooke A; Peral A; Hoyle CH; Pintor J
    Prog Retin Eye Res; 2007 Nov; 26(6):674-87. PubMed ID: 17931952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension.
    Martinez A; Sanchez M
    Expert Opin Pharmacother; 2008 Jan; 9(1):137-43. PubMed ID: 18076345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
    Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
    J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results?
    Parrish RK
    Curr Opin Ophthalmol; 2006 Apr; 17(2):138-41. PubMed ID: 16552248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment.
    Stjernschantz J
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():63-8. PubMed ID: 7732906
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ocular hypertension--follow up or treatment?].
    Stefan C; Dumitrica DM; Dragomir L; Cristea I; Sapundgieva A
    Oftalmologia; 2009; 53(2):23-5. PubMed ID: 19697835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
    Magacho L; Reis R; Shetty RK; Santos LC; Avila MP
    Ophthalmology; 2006 Mar; 113(3):442-5. PubMed ID: 16458964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oculohypotensive effects of foeniculum vulgare in experimental models of glaucoma.
    Agarwal R; Gupta SK; Agrawal SS; Srivastava S; Saxena R
    Indian J Physiol Pharmacol; 2008; 52(1):77-83. PubMed ID: 18831355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.